Integral to the pre-clinical and clinical evaluation of mAb drugs is the detection of the drug in biological samples to evaluate dose, toxicity and efficacy. Anti-idiotypic antibodies are critical reagents for the development of bioanalytical assays for such evaluations.
If you have invested in high technology platforms for discovery of your mAb drug, and appreciate the specificity, affinity and flexibility achievable with these, why revert back to animal generated monoclonal or polyclonal antibodies as research tools to support the drug's clinical evaluation?
When you outsource generation of recombinant monoclonal anti-idiotypic antibodies to Bio-Rad you can bypass internal bottlenecks faced accessing the platforms prioritised for therapeutic drug discovery. You receive the highly specific antibodies you need in a matter of weeks, rather than months, and have a long-term secure supply to support clinical evaluation of your drug.
Choose HuCAL technology to make your anti-idiotypic antibodies
At Bio-Rad we have been generating recombinant monoclonal antibodies for our customers’ individual requirements since 2003 using HuCAL (Human Combinatorial Antibody Library) and CysDisplay (a proprietary method of phage display).
For anti-idiotypic antibody projects, selection of the antibody is carried out on the drug in the presence of isotype sub-class matched antibodies as blockers, to avoid enrichment of specificities that bind to other regions of the antibody drug and to ensure idiotope specificity. Additionally, selection is performed in the presence of human serum to avoid matrix effects in the final assay.
Find out more about the custom service we offer using HuCAL technology, and contact us to discuss how our experts can design a strategy to make anti-idiotypic antibodies to your unique biotherapeutic target.